AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.
Bloomberg noted that the action won't affect development of the ovarian cancer treatment.
AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.
Shares of AstraZeneca are indicated lower Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shire plc (SHPG) Sees Weakness
- Rockwell Automation (ROK) calls expiring today active as shares rally
- Valeant's (VRX) Weak Business Could Force it to Refinance Debt - Wells Fargo's Maris
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!